FNY Partners Fund LP bought a new position in Akorn, Inc. (NASDAQ:AKRX) during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 11,190 shares of the company’s stock, valued at approximately $371,000.

Other large investors have also recently bought and sold shares of the company. Zurcher Kantonalbank Zurich Cantonalbank lifted its position in shares of Akorn by 22.8% in the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 3,228 shares of the company’s stock worth $108,000 after buying an additional 599 shares in the last quarter. Victory Capital Management Inc. raised its position in Akorn by 17.6% during the second quarter. Victory Capital Management Inc. now owns 4,177 shares of the company’s stock valued at $140,000 after purchasing an additional 626 shares during the period. LMR Partners LLP purchased a new stake in Akorn during the third quarter valued at approximately $200,000. Cubist Systematic Strategies LLC purchased a new stake in Akorn during the second quarter valued at approximately $209,000. Finally, World Asset Management Inc purchased a new stake in Akorn during the second quarter valued at approximately $210,000. Institutional investors own 73.44% of the company’s stock.

Shares of Akorn, Inc. (AKRX) opened at $32.64 on Tuesday. The company has a quick ratio of 3.17, a current ratio of 4.16 and a debt-to-equity ratio of 0.92. Akorn, Inc. has a fifty-two week low of $17.61 and a fifty-two week high of $34.00. The firm has a market capitalization of $4,078.55, a P/E ratio of 20.25, a PEG ratio of 1.94 and a beta of 1.33.

In other news, Director Brian Tambi sold 15,100 shares of the stock in a transaction that occurred on Tuesday, November 21st. The stock was sold at an average price of $33.35, for a total value of $503,585.00. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Corporate insiders own 28.20% of the company’s stock.

A number of equities research analysts have issued reports on the company. Piper Jaffray Companies restated a “hold” rating and set a $34.00 price objective on shares of Akorn in a research report on Thursday, August 10th. TheStreet downgraded Akorn from a “b-” rating to a “c” rating in a research report on Tuesday, August 1st. BidaskClub downgraded Akorn from a “hold” rating to a “sell” rating in a research report on Tuesday, August 1st. Royal Bank Of Canada restated a “sector perform” rating and set a $34.00 price objective on shares of Akorn in a research report on Sunday, August 20th. Finally, Zacks Investment Research upgraded Akorn from a “strong sell” rating to a “hold” rating in a research report on Tuesday, October 24th. Three analysts have rated the stock with a sell rating, nine have given a hold rating and one has assigned a buy rating to the company’s stock. Akorn currently has an average rating of “Hold” and an average price target of $29.38.

TRADEMARK VIOLATION WARNING: This article was originally reported by Watch List News and is the property of of Watch List News. If you are viewing this article on another website, it was stolen and republished in violation of U.S. & international trademark and copyright laws. The correct version of this article can be accessed at https://www.watchlistnews.com/fny-partners-fund-lp-invests-371000-in-akorn-inc-akrx/1730205.html.

Akorn Profile

Akorn Inc (Akorn), together with its subsidiaries, is a specialty generic pharmaceutical company that develops, manufactures and markets generic and branded prescription pharmaceuticals, as well as private-label over-the-counter (OTC) consumer health products and animal health pharmaceuticals. The Company operates through two segments: Prescription Pharmaceuticals and the Consumer Health.

Want to see what other hedge funds are holding AKRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Akorn, Inc. (NASDAQ:AKRX).

Institutional Ownership by Quarter for Akorn (NASDAQ:AKRX)

Receive News & Ratings for Akorn Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akorn Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.